Repository logo
  • English
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Log In
    or
    New user? Click here to register.
Repository logo

Repositorio Institucional de la Universidad de Murcia

Repository logoRepository logo
  • Communities & Collections
  • All of DSpace
  • Statistics
  • menu.section.collectors
  • menu.section.acerca
  • English
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Latviešu
  • Magyar
  • Nederlands
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Log In
    or
    New user? Click here to register.
  1. Home
  2. Browse by Subject

Browsing by Subject "Tumor grading"

Now showing 1 - 1 of 1
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Publication
    Open Access
    AHNAK2 is a novel diagnostic biomarker for gallbladder adenocarcinoma
    (2026) Qi Song; Lei Xu; Xinyi Zhang; Minying Deng; Jie Huang; Jieakesu Su; Huimei Wang; Yingyong Hou; Lingli Chen; Biología Celular e Histología; Universidad de Murcia, Departamento de Biologia Celular e Histiologia
    Objective. To investigate the pathological diagnostic value of AHNAK2 in gallbladder carcinoma (GBC), especially in adenocarcinoma (AC). Methods. Tissue microarrays (TMAs) were constructed from 296 gallbladder tumor cases, comprising 562 cores that included normal/atypical epithelium, low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia/carcinoma in situ (HGIN/TIS), and GBC. Immunohistochemical staining for AHNAK2 and IMP3 was performed on these TMAs and another 10 GBC cases, and the sensitivity and specificity of AHNAK2 were assessed across different gallbladder tumor types. Results. AHNAK2 immunohistochemical expression demonstrated a progressive increase across pathological stages (p<0.001). Among tumor types, AHNAK2 positivity was observed in 67.53% (260/385) of ACs, 97.83% (45/46) of adenosquamous/squamous cell carcinomas (ASC/SCCs), 34.78% (8/23) of neuro endocrine carcinomas/mixed neuroendocrine-non neuroendocrine neoplasms (NEC/miNEN), but not in areas of NECs, and none in undifferentiated carcinomas (UCs). Importantly, among three grades of well, moderately, and poorly differentiated AC, the positive rate of AHNAK2 decreased from 70.59% (24/34), 70.11% (190/271), to 57.50% (46/80); conversely, IMP3 increased from 58.82%, 78.97% to 83.75%. Given the extremely low positivity rates of AHNAK2 and IMP3 in normal/atypical epithelium, combining these markers significantly improved diagnostic performance, demonstrating 83.73% sensitivity and 91.38% specificity for HGIN/TIS and GBC, achieving sensitivities of 91.18%, 90.77%, and 93.75% across well, moderately, and poorly differentiated ACs. Conclusion. AHNAK2 demonstrates moderate sensitivity and high specificity in the pathological diagnosis of GBC, particularly for well-differentiated ACs. Combining AHNAK2 with IMP3 significantly enhances diagnostic sensitivity, achieving up to 90% across all AC grades.

DSpace software copyright © 2002-2026 LYRASIS

  • Cookie settings
  • Accessibility
  • Send Feedback